Pharmaceutical Executive November 3, 2023
Due to a global demand, treatments such as Adderall and Ritalin have been in short supply for the management of attention-deficit hyperactivity disorder.
Over the past few years, a combination of supply chain issues and rising diagnoses of attention-deficit hyperactivity disorder (ADHD) has led to a major shortage of medicines focused on treating individuals with the disorder. During the height of the COVID-19 pandemic in 2020, The American Medical Association labeled the limited inventory as an urgent public health crisis.1-3
In the United States, studies have found that the biggest contributor to the rising demand for ADHD drugs was young adults, aged 22 to 44 years, with prescriptions for the most commonly used drug rising by approximately 50% in this...
Today's Sponsors
Today's Sponsor